CY1107062T1 - ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ - Google Patents
ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥInfo
- Publication number
- CY1107062T1 CY1107062T1 CY20071100883T CY071100883T CY1107062T1 CY 1107062 T1 CY1107062 T1 CY 1107062T1 CY 20071100883 T CY20071100883 T CY 20071100883T CY 071100883 T CY071100883 T CY 071100883T CY 1107062 T1 CY1107062 T1 CY 1107062T1
- Authority
- CY
- Cyprus
- Prior art keywords
- optional
- activators
- medicines
- active substances
- competitive activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τη χρήση δραστικών ουσιών με δράση αγωνιστή μ-υποδοχέα οπιοειδών και ως φαρμακευτικά μέσα συνδυασμού για την αντιμετώπιση καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10142996A DE10142996A1 (de) | 2001-09-01 | 2001-09-01 | Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung |
EP02767251A EP1420789B1 (de) | 2001-09-01 | 2002-07-23 | VERWENDUNG VON WIRKSTOFFEN MIT µ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107062T1 true CY1107062T1 (el) | 2012-10-24 |
Family
ID=7697464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100883T CY1107062T1 (el) | 2001-09-01 | 2007-07-03 | ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050043280A1 (el) |
EP (1) | EP1420789B1 (el) |
AT (1) | ATE360420T1 (el) |
CY (1) | CY1107062T1 (el) |
DE (2) | DE10142996A1 (el) |
DK (1) | DK1420789T3 (el) |
ES (1) | ES2286280T3 (el) |
PT (1) | PT1420789E (el) |
WO (1) | WO2003020277A1 (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10237056A1 (de) * | 2002-08-09 | 2004-03-04 | Grünenthal GmbH | Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin |
DE10237057A1 (de) * | 2002-08-09 | 2004-03-25 | Grünenthal GmbH | Opioid-Rezeptor-Antagonisten in Pflasterformulierungen |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US8301839B2 (en) * | 2005-12-30 | 2012-10-30 | Citrix Systems, Inc. | System and method for performing granular invalidation of cached dynamically generated objects in a data communication network |
EP1810714A1 (de) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution |
CA2752849C (en) | 2009-07-24 | 2014-07-08 | Bernd G. Seigfried | Liquid compositions capable of foaming and including active agents, and methods for making or developing same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
ATE323491T1 (de) * | 1997-12-22 | 2006-05-15 | Euro Celtique Sa | Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon |
-
2001
- 2001-09-01 DE DE10142996A patent/DE10142996A1/de not_active Ceased
-
2002
- 2002-07-23 WO PCT/EP2002/008181 patent/WO2003020277A1/de active IP Right Grant
- 2002-07-23 PT PT02767251T patent/PT1420789E/pt unknown
- 2002-07-23 DK DK02767251T patent/DK1420789T3/da active
- 2002-07-23 EP EP02767251A patent/EP1420789B1/de not_active Expired - Lifetime
- 2002-07-23 ES ES02767251T patent/ES2286280T3/es not_active Expired - Lifetime
- 2002-07-23 US US10/488,081 patent/US20050043280A1/en not_active Abandoned
- 2002-07-23 AT AT02767251T patent/ATE360420T1/de not_active IP Right Cessation
- 2002-07-23 DE DE50210037T patent/DE50210037D1/de not_active Expired - Fee Related
-
2007
- 2007-07-03 CY CY20071100883T patent/CY1107062T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003020277A1 (de) | 2003-03-13 |
US20050043280A1 (en) | 2005-02-24 |
DK1420789T3 (da) | 2007-09-17 |
ATE360420T1 (de) | 2007-05-15 |
DE10142996A1 (de) | 2003-03-27 |
EP1420789B1 (de) | 2007-04-25 |
ES2286280T3 (es) | 2007-12-01 |
EP1420789A1 (de) | 2004-05-26 |
PT1420789E (pt) | 2007-07-03 |
DE50210037D1 (de) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118921T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη | |
CY1106600T1 (el) | Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
CY1114420T1 (el) | Φαρμακευτικη συνθεση για δερματικη χρηση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη για την αγωγη της ψωριασης | |
CY1107062T1 (el) | ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ | |
PT1041987E (pt) | Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona | |
YU42402A (sh) | Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor | |
CY1111458T1 (el) | Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης | |
EA200600696A1 (ru) | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств | |
DK1526839T3 (da) | Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed | |
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
TR200200359T2 (tr) | Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması | |
SE0302488D0 (sv) | New combination | |
ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
CY1107739T1 (el) | Ανταγωνιστες υποδοχεων οπιοειδων σε διαδερματικα συστηματα με μπουπρενορφινη | |
TR200200913T2 (tr) | Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. | |
HUP0202847A2 (hu) | Inszekticid és akaricid hatású szinergetikus hatóanyag-kombinációk, előállításuk és alkalmazásuk | |
PT1497292E (pt) | Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos | |
BR0213574A (pt) | Compostos básicos lineares apresentando atividade antagonista do nk-2 e formulações contendo os mesmos | |
IL156069A0 (en) | Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma | |
SE0000303D0 (sv) | Novel compounds | |
BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
SE0203817D0 (sv) | New composition | |
PT942729E (pt) | Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse |